



RESEARCH ARTICLE

Surgical Site Infection after Liver Transplantation: Single-Center Experience

Kenneth A Softness, Ahmed El Sabbagh, Alexander Kroemer, Jason Hawksworth, Cal S Matsumoto, Thomas Fishbein and Raffaele Girlanda*



Med Star Georgetown Transplant Institute, Georgetown University Hospital, USA

*Corresponding author: Raffaele Girlanda, MD, Associate Professor of Surgery, Georgetown University Hospital, Transplant Institute, PHC Building, 2nd floor, 3800 Reservoir Road, NW, Washington DC 20007, USA, Tel: +202-444-3700, Fax: 202-444-1170

Abstract

Infections are frequent complications after liver transplantation. The impact of surgical site infections on patient outcome remains unclear. The aim of our retrospective study is to analyze the incidence and predictors of surgical site infections after liver transplant at our program and to determine their impact on patient outcome. Twenty-four (9.5%) surgical site infections were recorded among 252 liver transplants performed between January 2011 and December 2013. Among perioperative variables, re-transplantation was the only significant risk factor on univariate analysis ($P = 0.015$, CI 1.448-29.259), whereas age, gender, ethnicity, MELD score, donor type and cold ischemia time were not. The length of hospital stay was increased in the surgical site infection group (median 12 (5-152)) compared to the rest of the patients (median 9 (5-145)) ($p = 0.032$), while rejection rate was lower although not significantly different (0% versus 4.4%) ($p = 0.295$). Patient and graft survival at 1, 3 and 5 years were lower in the SSI group compared to non-SSI ($p = 0.001$ and 0.003, respectively).

Conclusion: In our experience, re-transplants pose higher risk for SSI compared to primary transplants. SSI increase the length of hospital stay and impact negatively on survival after liver transplantation.

Keywords

Immunosuppression, Organ transplant, Post-transplant complications, Nosocomial infection, Risk factors

Abbreviations

LT: Liver Transplantation; SSI: Surgical Site Infection; DCD: Donation after Circulatory Determination of Death; MELD: Model for End-stage Liver Disease

Introduction

Liver transplantation (LT) is an established treatment for patients with acute and chronic liver failure. Currently over 6,000 liver transplants are performed every year in the US and the outcomes have improved dramatically over the last two decades compared to the early era due to the refinement of the surgical technique, more effective immunosuppression and better peri-operative care, including infection prophylaxis [1]. As a result, current 1-year survival rates approach 90% in many centers. Nevertheless, infections remain frequent complications after LT with a potential negative impact on outcomes. The most common infections after LT involve the surgical wound, the abdominal cavity, the biliary tract, the lung and the bloodstream [2,3]. In previous studies, SSI after LT have been associated with increased mortality, readmission rates and costs [4]. Recently, the emergence of multi-drug resistant bacteria has raised concern [1,5] calling for an increased awareness and updated management of SSI after LT.

The rate of surgical site infections (SSI) has been used recently by regulatory agencies as a measure of quality of care and several studies have appeared in the surgical [6,7] and transplant [8,9] literature on the incidence and impact of SSI. However, the applicability to transplant recipients of quality metrics adopted in the general surgical population is not well established. The clinical condition of transplant recipients both pre-

and post-transplant is usually more complex than the general surgery population due to the effects of end-stage organ failure, poor general medical and nutritional status, frequent pre-transplant hospitalization, use of invasive equipment and vascular access, prolonged operative time and immunosuppression. As a result, LT patients are more likely to develop SSI compared to the general surgery population. Therefore, effective strategies to prevent SSI are needed in an attempt to constantly improve outcomes after LT.

The Center for Disease Control defined SSI as infections occurring within 30 days after the operation and classified them as superficial (limited to the skin and subcutaneous tissue), deep (involving the fascial and muscle layers) or organ-space infections (extending beyond fascia and muscle layer [10]). In the general surgery patient population, risk factors for SSI are the presence of coincident infections, pre-operative nares colonization with *S. aureus*, diabetes, cigarette smoking, obesity and the extremes of age [11]. Additionally, four operative variables were identified by the Study of Efficacy of Nosocomial Infection Control (SENIC) as independent predictors of SSI including abdominal operation, surgical time greater than 2 hours, contaminated or dirty/infected site as well as multiple co-morbidities [11]. In LT, the risk factors for SSI and the impact on outcomes are poorly defined.

The aim of our study is to review the experience at our program with SSI after LT and to analyze their incidence, predictors, and outcomes, including impact on survival.

Experimental Procedures

We conducted a retrospective analysis of all adult patients (age ≥ 18 years) undergoing primary liver transplant, re-transplant or simultaneous liver-kidney transplant at our institution between 2011 and 2013. Multi-visceral transplants (liver-small bowel, liver-pancreas) were excluded. The study was approved by the Institutional Review Board.

The electronic medical records and the prospectively maintained transplant databases were reviewed to analyze the incidence, clinical presentation, microbiology, treatment and outcome of patients who experienced SSI after LT. Patients with SSI were identified by reviewing all microbiology records, operative notes, radiology reports and discharge summaries. SSI were classified according to CDC as superficial, deep and organ space [10]. In order to capture patients with prolonged hospital stay and complex post-operative course, we included in our analysis SSI occurring up to 90 days post-LT in contrast with the 30 days post-transplant interval of the original CDC definition. Other parameters analyzed in this study included donor, recipient and operative characteristics of all patients in the cohort.

All grafts were procured with standard technique from brain-dead donors or from donation after circulatory determination of death (DCD). The recipient operation included standard vena cava replacement technique without the use of veno-venous bypass. Recipients Model for End-Stage Liver Disease (MELD) score included in this analysis represents the native calculated score without exception points.

The immunosuppression protocol consisted of tacrolimus, mycophenolate mofetil and corticosteroids. In patients with SSI the immunosuppression regimen was modified as needed on an individual basis based on the risk profile. While the tacrolimus trough levels were generally maintained unchanged, mycophenolate mofetil dose was reduced or temporarily discontinued and steroid dose was tapered.

Peri-operative anti-bacterial prophylaxis consisted of ampicillin and cefoxitin for the first 48-hours post-transplant. Anti-fungal and anti-viral prophylaxis included a combination of nystatin swish-and-swallow, micafungin, fluconazole, ganciclovir and valganciclovir for 3-6 months, depending on the risk profile. The post-transplant antimicrobial therapy was modified on an individual basis considering clinical factors and speciation of microbiology results.

The length of hospital stay was calculated from the date of transplant to the date of discharge, thus excluding any duration of hospital stay pre-transplant. SSI were diagnosed according to standard criteria (see above) and treated depending on severity. Superficial SSI were managed at the bedside with wound care and antibiotics, while deep and organ space SSI were treated either with percutaneous drainage by interventional radiology or with laparotomy and open surgical drainage, in addition to antibiotics.

Statistical Analysis

Continuous variables were expressed as median (range), categorical variables were expressed as percentage. The cumulative incidence of SSI, graft loss and death was estimated by using Kaplan-Meier method [12]. Univariate and multivariate analysis using the Cox proportional hazard model [13] was used to investigate the association between patient, donor and operative characteristics and development of SSI post-transplant. A similar analysis was undertaken to investigate the impact of SSI on patient and graft survival.

Results

The demographic characteristics of 252 adult recipients of a LT performed at our program between January 2011 and December 2013 included in this study are reported in (Table 1).

Among them, 23 (9%) patients developed 24 SSI at a median interval of 21 days (range 7-88) post-LT. According to the CDC classification of surgical site infections

Table 1: Patient characteristics.

Characteristic	Value
Patients	252
Males	178
Females	74
Age, median (range)	61 (22-74)
Ethnicity	
African American	67
Asian	29
Caucasian	137
Hispanic	15
Middle Eastern	4
Indications for Transplant	
Chronic Liver Disease	236 (94.4%)
Acute Liver Failure	8 (3.2%)
Re-transplant	8 (3.2)
Hepatocellular Carcinoma	70/252 (27.8%)
MELD, median (range)	19 (6-45)
DBD*	228/252 (90.5%)
DCD**	24/252 (9.5%)
Organ Type	
Whole Liver	226
Liver/Kidney	18
Split Liver	7
Domino	1
Cold Ischemia Time, median (range)	5.85 hours (1.78-16.98)

*DBD: Donation after neurologic determination of death; **DCD: Donation after determination of death by circulatory criteria.

(see Methods), there were 8 (33%) superficial, 4 (17%) deep and 12 (50%) organ space SSI. The clinical presentation, microbiology results and treatment course for each SSI are reported in (Table 2).

Microbiology culture results were available for 21 of 24 infections. Based on culture results, the infection was polymicrobial in 13/252 (5%) and monomicrobial in 8 (3%) patients. The remaining 3 patients were treated empirically for a culture-negative symptomatic SSI based on clinical presentation.

In addition to antimicrobial therapy, 13 (5%) patients required an invasive procedure for the treatment of SSI: 7 (3%) patients underwent percutaneous drainage by interventional radiology and 6 (2%) patients required re-operation. No patient died or lost the graft due to SSI in this cohort.

Among donor, recipient and operative characteristics, re-transplantation was associated with increased risk of SSI on univariate ($p = 0.015$) analysis (HR = 6.51 (1.448-29.259)), while other variables such as age, gender, race, MELD score, DCD status and cold ischemia time were not significantly different between patients who experienced SSI versus not (Table 3).

The duration of hospital stay was longer in patients with SSI (median 12 days (5-152)) compared to non-SSI

Table 2: Surgical site infections.

Type	Microbe	Treatment
Superficial (n = 8)	Rare Corynebacterium/Alpha Hemolytic Strep and Veilonella spp Gram neg anaerobic cocci	Bedside wound care and antibiotics
	VRE/Gm- Rods/ <i>E. Cloacae</i>	Bedside wound care and antibiotics
	<i>E. coli</i>	Bedside wound care and antibiotics
	Enterobacter/Coag Neg Staph	Antibiotics
	<i>Proteus mirabilis</i>	Antibiotics
	<i>S. aureus</i>	Bedside wound care and antibiotics
	Culture negative symptomatic infection	Empiric antibiotics
	Rare E fecium, few Coag Negative Staph	Antibiotics
Deep (n = 4)	Klebsiella/Pseudomonas	IR drainage and antibiotics
	Pseudomonas/Gm + Cocci/Enterobacter	Operative wound debridement and antibiotics
	Pseudomonas/Corynebacterium spp, /Enterococcus	Operative wound debridement and antibiotics
	MRSA	Operative wound debridement and antibiotics
Organ Space (n = 12)	Culture negative symptomatic abdominal fluid collection	IR drainage
	pl fluid <i>S. epidermidis</i> and <i>S. capitis</i>	IR drainage and antibiotics
	Pseudomonas/Gm- Rods	Laparotomy for repair of bowel perforation and antibiotics
	Rare Coag Negative Staph	Re-laparotomy for evacuation of hematoma and antibiotics
	<i>Candida tropicalis</i>	IR drainage and antifungals
	<i>Enterococcus faecium</i>	Laparotomy and antibiotics
	<i>E. faecalis</i> /Gm- + rods	IR drainage and antibiotics
	VRE and multidrug resistant <i>K pneumonia</i>	Paracentesis and antibiotics
	<i>C. albicans</i> , <i>C. glabrata</i>	Paracentesis and antifungals
	VRE/Gm + Cocci	IR drainage, endoscopic stent for biliary stricture and antibiotics
	Cryptococcus	IR drainage and antifungals
	Fever and abdominal fluid collection (no culture)	Empiric antibiotics

Table 3: Risk factors for surgical site infections.

Variable	Number	Univariate analysis	HR	HR (95% CI)
Recipient		P = 0.837	1.004	(0.966-1.044)
Age > 60				
Age < 60				
Sex				
Male		P = 0.722	1.176	(0.481-2.879)
Female				
Ethnicity				
African American	66	P = 0.072	0.303	(0.083-1.111)
Caucasian	137			
Hispanic	15	P = 0.557	0.53	(0.064-4.417)
Middle Eastern	4	P = 0.398	2.731	(0.266-27.987)
Other	1	P = 1.000		
MELD		P = 0.392	1.019	(0.976-1.065)
Indication				
ReTx	8	P = 0.015	6.51	(1.448-29.259)
Acute	7	P = 0.592	1.808	(0.207-15.774)
Chronic (reference)	237			
DCD				
Yes	22	P = 0.418	0.429	(0.055-3.335)
No	230			
CIT		P = 0.736	1.001	(0.966-1.005)

Risk Factors for Surgical Site Infections (SSI): Results of our univariate analysis to identify predictors of SSI. Among the donor, recipient and operative characteristics analyzed utilizing the cox regression model- only re-transplantation was associated with a significantly increased risk of SSI (P = 0.015).

Table 4: Outcomes.

Characteristics	Total (N = 252)	SSI group (N = 24)	Non SSI group (N = 228)	P value
Follow up period (months)	47.33 (0.53 - 68.93)	41.61 (1.28 - 65.81)	47.43 (0.53 - 68.93)	P = 0.128
Overall mortality	51 (20.2%)	10 (41.7%)	41 (18%)	P = 0.006
Overall survival				
1 Year	84%	58%	86%	P = 0.001
3 Year	80%	58%	82%	
5 Year	79%	58%	81%	
Overall graft loss	54 (21.4%)	10 (41.7%)	44 (19.3%)	P = 0.011
Overall graft survival				
1 Year	82%	58%	85%	P = 0.003
3 Year	78%	58%	80%	
5 Year	78%	58%	80%	

Impact of Surgical Site Infection (SSI) on rejection rate and length of stay: We can conclude that SSI is not a significant risk factor for rejection, however SSI does significantly prolong hospital stay.

patients (9 days (5-145), p = 0.032). We also concluded that SSI is not a significant risk factor for rejection, which was of particular interest to us considering that patients with clinical suspicion for infection have their immunosuppression reduced (Table 4).

There were 10/252 (4%) episodes of biopsy-proven acute cellular rejection in the present cohort during the study period of 90-days post-transplant, none of which occurred in patients with SSI.


After a median follow-up of 47 months, patient survival at 1, 3, 5 years was 84%, 80% and 79%. Survival in the SSI group was significantly different from survival in the non-SSI group at 1, 3 and 5 years. (p = 0.006). Similarly, graft survival was inferior in SSI patients (58%, 58%, 58% at 1, 3, 5 years) compared to non-SSI (85%, 80%, 80%, p = 0.003) (Figure 1).

Discussion

In this retrospective study we found that the current incidence of SSI at our program is 9.5%. In our series, 24 SSI occurred in 23/252 patients after LT. One patient developed two SSI's caused by different microorganisms: a superficial wound infection on day 18 and abdominal fluid collection on day 44 growing corynebacterium and alpha-hemolytic streptococcus.

Previous studies from other centers reported the frequency of SSI after LT between 8 and 37% and the variability is likely due to different definitions and patient selection [4,14-18].

SSI as classified by the CDC National Nosocomial Infection Surveillance system occur within 30 days of surgery. However, in our data collection we broadened the post-LT interval to 90 days after LT instead of only



the first 30 days in order to capture late infections occurring in patients with prolonged post-LT course. Unlike in most elective general surgery operations, the recovery period after LT can be prolonged and complicated, occasionally extending for several weeks, especially in high MELD patients due to the advanced disease state of transplant candidates and the associate multi-organ system involvement, such as acute kidney injury and others. As a result, in such debilitated patients, SSI may occur beyond the first 30 post-operative days and would not be captured by the current definition. We believe that the expansion of the post-LT period of surveillance for SSI to 90 days more accurately reflect the severity of their disease and more reliably captures relevant infections that would have otherwise not been included. Other studies adopted this wider post-LT interval up to 90 days [19] including the very first study on this subject where the study interval was extended up to one-year post-LT [16]. The current low rate of SSI in our experience results from a combination of effective peri-operative infection prophylaxis, close patient monitoring and individualized immunosuppression management. However, their frequency remains higher compared with the incidence of SSI in the general surgery population reported between 2-4% [10] highlighting, among other factors, the impact of the immunosuppression state on the increased risk of infection.

In addition to immunosuppression, several operative characteristics, including the length of operative time, impact on the risk of SSI after LT. Previous studies emphasized that the risk of surgical site infection can be stratified based on operative time [20]. Our length of operative time for LT is usually between 4-6 hours depending on the complexity of the case (data not reported) and this duration of the operation is

significantly longer compared to the threshold of 2 hours previously reported in general surgery patients [11].

Other transplant-specific risk factors for intra-abdominal infection post-LT have been identified including the type of biliary anastomosis (duct-to-duct versus roux-en-y hepatico-jejunostomy, due to the putative protective effect of preserving the native Sphincter of Oddi) and the occurrence of hepatic artery thrombosis post-LT [9,21]. Several other risk factors for SSI in LT recipients that have been reported include surgical complexity, poor nutritional status, comorbidities, frequent prolonged pre-transplant hospital stay, invasive procedures and use of intra-vascular catheters. Some of these factors are in common with patients undergoing non-transplant liver surgery whose reported incidence of SSI varies between 7 and 27%, attributed to hypoalbuminemia, dialysis, operative time and extent of liver resection [22]. In turn, these factors lead to increased risk of colonization with multi-drug-resistant organisms [23].

Other significant findings of our study are the increased length of stay and negative impact of SSI on survival. Prior studies reported that SSI after LT are associated with significant increase in resource utilization. In a multicenter study that examined 916 LT cases between 1990-1995, patients who developed SSI (292/916) incurred an extra \$160,000 in extra charges had 24 extra hospital stays on average. Further, SSI was the single most impactful factor on resource utilization when considering the cost of LT [16].

In our series the median length of stay was 4 days longer in the SSI group compared to non SSI. This has a direct impact on costs. A prior group reported that SSI patients were five times more likely to get readmitted to the hospital and twice as likely to die [15].

In addition to increasing costs, SSI also impact patient outcomes. In our experience SSI has a significant impact on patient and graft survival. This is in line with prior studies that showed that transplant patients with SSI are more likely to lose their graft, with a relative risk of graft loss or death within one year of transplant of 2.95. In the same study, the risk of graft loss or death was even greater when considering only deep or organ-space infections [4]. There is no general consensus on the most effective prevention strategy for SSI since many observations from prior studies are center-specific. According to the Cochrane Database Review from Almeida, et al. in 2015, no particular antibiotic prophylactic regimen has been identified so far to prevail over other regimens.

The strength in our study comes from a uniform protocol of single-center experience, a unified team of transplant surgeons and staff, infectious disease and transplant hepatology consultants. The detailed chart review was performed by a single investigator, ensuring all charts were reviewed in the same detailed and systematic fashion. The single-center experience is also a limitation of the study, in that it limits the overall number of patients that can be analyzed. Our results are therefore difficult to generalize to other programs. The limited sample size prevented a more meaningful multivariate analysis which would have allowed us to identify potential causal relationships between certain characteristics and SSI. The retrospective nature of this chart review may have also failed to identify certain empirically treated infections that lacked proper documentation. Finally, we did not evaluate the impact of induction immunosuppression on SSI.

In conclusion, patients undergoing re-transplantation are at a significantly increased risk for infections. SSI prolong the hospital stay and impact negatively on survival. Future studies are needed to identify independent predictors of surgical site infection and to design effective preventive strategies.

Acknowledgment

We are indebted to our Infectious Disease, Hepatology and Pharmacy colleagues and to the team of nurses and advanced care providers for excellent patient care.

References

- Singh N (1997) Infections in solid-organ transplant recipients. *Am J Infect Control* 25: 409-417.
- Bennett JE, Dolin R, Blaser MJ (2014) *Mandell, Douglas, and Bennett's principles and practice of infectious diseases*. Elsevier Health Sciences.
- Culver DH, Horan TC, Gaynes RP, Martone WJ, Jarvis WR, et al. (1991) Surgical wound infection rates by wound class, operative procedure, and patient risk index. National nosocomial infections surveillance system. *Am J Med* 91: 152S-157S.
- Hellinger WC, Crook JE, Heckman MG, Diehl NN, Shalev JA, et al. (2009) Surgical site infection after liver transplantation: Risk factors and association with graft loss or death. *Transplantation* 87: 1387-1393.
- Viehman JA, Clancy CJ, Clarke L, Shields RK, Silveira FP, et al. (2016) Surgical site infections after liver transplantation: Emergence of multidrug-resistant bacteria and implications for prophylaxis and treatment strategies. *Transplantation* 100: 2107-2114.
- Calderwood MS, Kleinman K, Huang SS, Murphy MV, Yokoe DS, et al. (2017) Surgical site infections: Volume-outcome relationship and year-to-year stability of performance rankings. *Med Care* 55: 79-85.
- Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ (1999) The impact of surgical-site infections in the 1990s: Attributable mortality, excess length of hospitalization, and extra costs. *Infect Control Hosp Epidemiol* 20: 725-730.
- Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, et al. (1995) Bacterial and fungal infections after liver transplantation: An analysis of 284 patients. *Hepatology* 21: 1328-1336.
- Kusne S (2008) Regarding the risk for development of surgical site infections and bacterial prophylaxis in liver transplantation. *Liver Transpl* 14: 747-749.
- Centers for Disease Control and Prevention. Surgical site infection.
- Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR (1999) Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. *Infect Control Hosp Epidemiol* 20: 250-278.
- Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. *American Statistical Association* 53: 457-481.
- Cox DR (1992) Regression models and life-tables. In: *Breakthroughs in statistics*. Springer, New York, 527-541.
- Almeida RA, Hasimoto CN, Kim A, Hasimoto EN, El Dib R (2015) Antibiotic prophylaxis for surgical site infection in people undergoing liver transplantation. *Cochrane Database Syst Rev*.
- Hellinger WC, Heckman MG, Crook JE, Taner CB, Willingham DL, et al. (2011) Association of surgeon with surgical site infection after liver transplantation. *Am J Transplant* 11: 1877-1884.
- Hollenbeak CS, Alfrey EJ, Souba WW (2001) The effect of surgical site infections on outcomes and resource utilization after liver transplantation. *Surgery* 130: 388-395.
- Freire MP, Soares Oshiro IC, Bonazzi PR, Guimarães T, Ramos Figueira ER, et al. (2013) Surgical site infections in liver transplant recipients in the model for end-stage liver disease era: An analysis of the epidemiology, risk factors, and outcomes. *Liver Transpl* 19: 1011-1019.
- Avkan-Oguz V, Unek T, Firuzan E, Ozbilgin M, Egeli T, et al. (2015) Bacterial pathogens isolated in liver transplant recipients with surgical site infection and antibiotic treatment. *Transplantation Proceedings* 47: 1495-1498.
- Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control* 36: 309-332.
- Leong G, Wilson J, Charlett A (2006) Duration of operation as a risk factor for surgical site infection: Comparison of English and US data. *J Hosp Infect* 63: 255-262.

21. Winston DJ, Emmanouilides C, Busuttil RW (1995) Infections in liver transplant recipients. *Clin Infect Dis* 21: 1077-1089.
22. Dorschner P, McElroy LM, Ison MG (2014) Nosocomial infections within the first month of solid organ transplantation. *Transpl Infect Dis* 16: 171-187.
23. Asensio A, Ramos A, Cuervas-Mons V, Cordero E, Sánchez-Turrión V, et al. (2008) Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. *Liver Transpl* 14: 799-805.